{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:00:38Z","timestamp":1791082838790,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40265-020-01335-7","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T08:03:04Z","timestamp":1591689784000},"page":"1041-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["New and Emerging Systemic Treatments for Atopic Dermatitis"],"prefix":"10.1007","volume":"80","author":[{"given":"Megan","family":"Newsom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-7567","authenticated-orcid":false,"given":"Arjun M.","family":"Bashyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-8838","authenticated-orcid":false,"given":"Esther A.","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay C.","family":"Strowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"4","key":"1335_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/imm.13120","volume":"158","author":"K Furue","year":"2019","unstructured":"Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M, et al. The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology. 2019;158(4):281\u20136. https:\/\/doi.org\/10.1111\/imm.13120.","journal-title":"Immunology"},{"issue":"5","key":"1335_CR2","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","volume":"135","author":"M Suarez-Farinas","year":"2015","unstructured":"Suarez-Farinas M, Ungar B, da Rosa CJ, Ewald DA, Rozenblit M, Gonzalez J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol. 2015;135(5):1218\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2015.03.003.","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"1335_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2018.10.032.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"1335_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.det.2017.02.005","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI, Kantor R. The role of interleukins 4 and\/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327\u201334. https:\/\/doi.org\/10.1016\/j.det.2017.02.005.","journal-title":"Dermatol Clin"},{"issue":"5","key":"1335_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaci.2019.06.047","volume":"144","author":"R Bissonnette","year":"2019","unstructured":"Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019;144(5):1274\u201389. https:\/\/doi.org\/10.1016\/j.jaci.2019.06.047.","journal-title":"J Allergy Clin Immunol."},{"issue":"7","key":"1335_CR6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.12.018.","journal-title":"J Invest Dermatol"},{"key":"1335_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","volume":"48","author":"E Guttman-Yassky","year":"2017","unstructured":"Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68\u201373. https:\/\/doi.org\/10.1016\/j.coi.2017.08.008.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"1335_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/ACI.0000000000000376","volume":"17","author":"B Cabanillas","year":"2017","unstructured":"Cabanillas B, Brehler A-C, Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol. 2017;17(4):309\u201315. https:\/\/doi.org\/10.1097\/ACI.0000000000000376.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"10023","key":"1335_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(15)00149-X.","journal-title":"Lancet"},{"issue":"4","key":"1335_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/exd.13336","volume":"27","author":"E Guttman-Yassky","year":"2018","unstructured":"Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Exp Dermatol. 2018;27(4):409\u201317. https:\/\/doi.org\/10.1111\/exd.13336.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1335_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2019","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2019;50(1):5\u201314. https:\/\/doi.org\/10.1111\/cea.13491.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"1335_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135\u201341. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.029.","journal-title":"J Allergy Clin Immunol."},{"issue":"24","key":"1335_CR13","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"5","key":"1335_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Thaci D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083\u2013101. https:\/\/doi.org\/10.1111\/bjd.16156.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1335_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2019","unstructured":"Deleuran M, Thaci D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2019;82(2):377\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.074.","journal-title":"J Am Acad Dermatol"},{"key":"1335_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3336","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 Randomized Clinical Trial. JAMA Dermatol. 2019. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336.","journal-title":"JAMA Dermatol."},{"issue":"2","key":"1335_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijd.14573","volume":"59","author":"C Wang","year":"2020","unstructured":"Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records. Int J Dermatol. 2020;59(2):253\u20136. https:\/\/doi.org\/10.1111\/ijd.14573.","journal-title":"Int J Dermatol"},{"key":"1335_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315010","author":"Y Nahum","year":"2019","unstructured":"Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2019. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315010.","journal-title":"Br J Ophthalmol"},{"key":"1335_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.039","author":"H Uchida","year":"2019","unstructured":"Uchida H, Kamata M, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, et al. Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting. J Am Acad Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.039.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1335_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjd.18476","volume":"182","author":"MJ Cork","year":"2019","unstructured":"Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2019;182(1):85\u201396. https:\/\/doi.org\/10.1111\/bjd.18476.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1335_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459\u201373. https:\/\/doi.org\/10.1111\/bjd.17869.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1335_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.18176\/jiaci.0301","volume":"28","author":"B Barroso-Garc\u00eda","year":"2018","unstructured":"Barroso-Garc\u00eda B, Rial MJ, Molina A, Sastre J. Alopecia areata in severe atopic dermatitis treated with dupilumab. J Investig Allergol Clin Immunol. 2018;28(6):420\u20131. https:\/\/doi.org\/10.18176\/jiaci.0301.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"1335_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdcr.2018.10.010","volume":"5","author":"K Flanagan","year":"2018","unstructured":"Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep. 2018;5(1):54\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2018.10.010.","journal-title":"JAAD Case Rep."},{"issue":"2","key":"1335_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jdcr.2017.11.020","volume":"4","author":"K Mitchell","year":"2018","unstructured":"Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018;4(2):143\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2017.11.020.","journal-title":"JAAD Case Rep."},{"issue":"5","key":"1335_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","volume":"151","author":"GC Mohan","year":"2015","unstructured":"Mohan GC, Silverberg JI. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151(5):522\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3324.","journal-title":"JAMA Dermatol."},{"issue":"1","key":"1335_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40257-019-00478-y","volume":"21","author":"AS Paller","year":"2020","unstructured":"Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21(1):119\u201331. https:\/\/doi.org\/10.1007\/s40257-019-00478-y.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1335_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjd.17791","volume":"181","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Simpson EL, Ardeleanu M, Thaci D, Barbarot S, Bagel J, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator\u2019s Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019;181(1):80\u20137. https:\/\/doi.org\/10.1111\/bjd.17791.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1335_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.18163","volume":"181","author":"H Uchida","year":"2019","unstructured":"Uchida H, Kamata M, Mizukawa I, Watanabe A, Agematsu A, Nagata M, et al. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. Br J Dermatol. 2019;181(5):1083\u20135. https:\/\/doi.org\/10.1111\/bjd.18163.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1335_CR29","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1111\/jdv.15118","volume":"33","author":"R Ruiz-Villaverde","year":"2019","unstructured":"Ruiz-Villaverde R, Dominguez-Cruz J, Armario-Hita JC, Martinez-Pilar L, Alcantara-Luna S, Pereyra-Rodriguez JJ. Dupilumab: short-term effectiveness and security in real clinical practice - A retrospective multicentric study. J Eur Acad Dermatol Venereol. 2019;33(1):e21\u20132. https:\/\/doi.org\/10.1111\/jdv.15118.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1335_CR30","unstructured":"LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD. 2019. https:\/\/via.ritzau.dk\/pressemeddelelse\/leo-pharma-announces-positive-top-line-results-for-tralokinumab-from-three-phase-3-studies-in-adult-patients-with-moderate-to-severe-ad?publisherId=12353927&releaseId=13584831. Accessed 2 Apr 2020."},{"issue":"3","key":"1335_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.dmpk.2017.12.001","volume":"33","author":"P Baverel","year":"2018","unstructured":"Baverel P, She D, Piper E, Ueda S, Yoshioka T, Faggioni R, et al. A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. Drug Metab Pharmacokinet. 2018;33(3):150\u20138. https:\/\/doi.org\/10.1016\/j.dmpk.2017.12.001.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"1335_CR32","doi-asserted-by":"publisher","first-page":"863-71e11","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-71e11. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.017.","journal-title":"J Am Acad Dermatol."},{"key":"1335_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b Randomized Clinical Trial. JAMA Dermatol. 2020. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079.","journal-title":"JAMA Dermatol."},{"issue":"9","key":"1335_CR34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1606490.","journal-title":"N Engl J Med"},{"issue":"1","key":"1335_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","volume":"145","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2019;145(1):173\u201382. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.013.","journal-title":"J Allergy Clin Immunol."},{"issue":"2","key":"1335_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"O Nemoto","year":"2016","unstructured":"Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174(2):296\u2013304. https:\/\/doi.org\/10.1111\/bjd.14207.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1335_CR37","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","volume":"142","author":"K Kabashima","year":"2018","unstructured":"Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121\u201330. https:\/\/doi.org\/10.1016\/j.jaci.2018.03.018.","journal-title":"J Allergy Clin Immunol."},{"issue":"2","key":"1335_CR38","doi-asserted-by":"publisher","first-page":"482-93e7","DOI":"10.1016\/j.jaci.2018.11.053","volume":"144","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(2):482-93e7. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.053.","journal-title":"J Allergy Clin Immunol."},{"issue":"4","key":"1335_CR39","doi-asserted-by":"publisher","first-page":"913-21e9","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913-21e9. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.018.","journal-title":"J Am Acad Dermatol."},{"key":"1335_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.18898.","journal-title":"Br J Dermatol"},{"key":"1335_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855.","journal-title":"JAMA Dermatol."},{"key":"1335_CR42","unstructured":"Pfizer Announces Positive Top-line Results From Phase 3 Study of Investigational Oral Jak1 Candidate, Abrocitinib (Pf-04965842), in Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis. 2019. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis. Accessed 10 Apr 2020."},{"issue":"11","key":"1335_CR43","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind. Randomized Controlled Trial. Arthritis Rheumatol. 2019;71(11):1788\u2013800. https:\/\/doi.org\/10.1002\/art.41032.","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"1335_CR44","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, Hong HC-H, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025.","journal-title":"J Allergy Clin Immunol"},{"key":"1335_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00905-7","author":"G Agnihotri","year":"2020","unstructured":"Agnihotri G, Lio PA. revisiting therapies for atopic dermatitis that failed clinical trials. Clin Drug Investig. 2020. https:\/\/doi.org\/10.1007\/s40261-020-00905-7.","journal-title":"Clin Drug Investig."},{"key":"1335_CR46","unstructured":"Park B. Tradipitant Misses Primary End Point in Atopic Dermatitis Trial. 2020. https:\/\/www.empr.com\/home\/news\/tradipitant-misses-primary-end-point-in-atopic-dermatitis-trial\/. Accessed 8 Apr 2020."},{"key":"1335_CR47","unstructured":"Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis. 2019. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-announces-top-line-phase-3-results-baricitinib-patients. Accessed 8 Apr 2020."},{"key":"1335_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/jaa.S206387","volume":"13","author":"M Napolitano","year":"2020","unstructured":"Napolitano M, Fabbrocini G, Cinelli E, Stingeni L, Patruno C. Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging clinical evidence. J Asthma Allergy. 2020;13:89\u201394. https:\/\/doi.org\/10.2147\/jaa.S206387.","journal-title":"J Asthma Allergy."},{"issue":"2","key":"1335_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.immuni.2011.12.015","volume":"36","author":"JJ Babon","year":"2012","unstructured":"Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity. 2012;36(2):239\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2011.12.015.","journal-title":"Immunity"},{"issue":"12","key":"1335_CR50","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843\u201362. https:\/\/doi.org\/10.1038\/nrd.2017.201.","journal-title":"Nat Rev Drug Discov."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01335-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:14:48Z","timestamp":1744701288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01335-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01335-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"9 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding sources"}},{"value":"Lindsay Strowd has received grants or support from Galderma, Pfizer, Actelion, and Sanofi Regeneron. Steven Feldman has received research, speaking, and\/or consulting support from a variety of companies including Galderma, GSK\/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation. He is founder and majority owner of\n                      \n                      and founder and part owner of Causa Research, a company dedicated to enhancing patients\u2019 adherence to treatment. Megan Newsom, Arjun Bashyam, and Esther Balogh have no conflicts to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}